Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab vs Rituximab in Relapsed Indolent B-Cell Non-Hodgkin Lymphoma
2010-018780-42Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ofatumumab in mature B-cell lymphoma (2 arms), sponsored by Novartis. Primary endpoint: Progression-free survival. Started Jun 2010; status: completed.
02
Drugs
ofatumumab
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on 2010-018780-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018780-42.